Tüberküloz Tedavisinde Kullanılan İlaçlar ve Etki Mekanizmaları
Referanslar
World Health Organization. Global tuberculosis report 2025. Geneva: World Health Organization; 2025.
Lehmann KB, Neumann R. Atlas und Grundriss der Bakteriologie und Lehrbuch der speziellen bakteriologischen Diagnostik. Munich: JF Lehmann; 1896.
Eker E. Anti-tüberküloz ilaçlar: dün, bugün, yarın: direnç ve etki mekanizmaları. Ankara: İKSAD Yayınevi; 2025.
Tille PM, editor. Bailey & Scott’s diagnostic microbiology. 16th ed. St. Louis: Elsevier; 2026. p. 553–557.
Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946–1986, with relevant subsequent publications. International Journal of Tuberculosis and Lung Disease. 1999;3(10 Suppl 2):S231–S279.
Zhang Y, Wu R, Sun M, Li X, Fang R, Xing J, Li Z, Wen Y, Song N. Progress of anti-tuberculosis drug targets and novel therapeutic strategies. Frontiers in Microbiology.2025;16:1637254. doi:10.3389/fmicb.2025.1637254
T.C. Sağlık Bakanlığı. Tüberküloz tanı ve tedavi rehberi. 3. baskı. Ankara: T.C. Sağlık Bakanlığı; 2026. ISBN: 978-625-93191-3-1 Sağlık Bakanlığı Yayın No: 1387
Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis: an official ATS/CDC/ERS/IDSA clinical practice guideline. American Journal of Respiratory and Critical Care Medicine.2019;200(10):e93–e142. doi:10.1164/rccm.201909-1874ST
World Health Organization. Key updates to the treatment of drug-resistant tuberculosis: rapid communication. Geneva: World Health Organization; 2024.
World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment and care. Geneva: World Health Organization; 2025.
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019.
US FDA. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. Aug 14, 2019. https://www. fda.gov/news-events/press-announcements/ fda-approves-new-drug-treatment-resistant forms-tuberculosis-affects-lungs.
Nyang’wa B-T, Berry C, Kazounis E, et al. A 24-week, all-oral regimen for rifampin resistant tuberculosis. New England Journal of Medicine. 2022; 387: 2331–43.
World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment—drug resistant tuberculosis treatment, 2022 update. Dec 15, 2022. https://www.who.int/ publications/i/item/9789240063129
Robitzek I, Selikoff IJ. Hydrazine derivatives of isonicotinic acid: treatment of tuberculosis. Journal of the American Medical Association. 1952;150(17):1579–1584. doi:10.1001/Journal of the American Medical Association.1952.02930220007002
Sotgiu G, Centis R, D'ambrosio L, et al. Tuberculosis treatment and drug regimens. Cold Spring Harbor Perspectives in Medicine.2015;5(5):a017822. doi: 10.1101/cshperspect.a017822
Vilchèze C, Jacobs WR Jr. The mechanism of isoniazid killing: clarity through the scope of genetics. Annual Review of Microbiology. 2007;61:35–50. doi: 10.1146/annurev.micro.61.111606.122346
Lei B, Wei CJ, Tu SC. Action mechanism of antitubercular isoniazid: activation by Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor. Journal of Biological Chemistry. 2000;275(4):2520–2526. doi:10.1074/jbc.275.4.2520
Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994;263(5144):227–230. doi:10.1126/science.8284673
Rozwarski DA, Grant GA, Barton DHR, et al. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Nature Structural Biology. 1998;5(2):113–117. doi: 10.1126/science.279.5347.98.
Daffé M, Draper P. The envelope layers of mycobacteria with reference to their pathogenicity. Advances in Microbial Physiology.. 1998;39:131–203. doi: 10.1016/s0065-2911(08)60016-8
Minnikin DE, Kremer L, Dover LG, et al. The methyl-branched fortifications of Mycobacterium tuberculosis. Chemistry & Biology. 2002;9(10):545–553. doi: 10.1016/s1074-5521(02)00142-4
Brennan PJ, Nikaido H. The envelope of mycobacteria. Annual Review of Biochemistry. 1995;64:29–63. doi:10.1146/annurev.bi.64.070195.000333
Jackson M, Crick DC, Brennan PJ. Phosphatidylinositol is a major phospholipid of the Mycobacterium tuberculosis cell envelope. Microbiology. 1999;145(9):2551–2563. doi:10.1099/00221287-145-9-2551
Daffé M. The cell envelope of tubercle bacilli. Tuberculosis. 2015;95(Suppl 1):S155–S158. doi:10.1016/j.tube.2015.02.024
Brennan PJ. Structure, function, and biogenesis of the cell envelope of mycobacteria. Tuberculosis (Edinburgh, Scotland). 2003;83(1–3):91–97. doi:10.1016/S1472-9792(02)00089-6
Jaladanki CK, Shaikh A, Bharatam PV. Biotransformation of Isoniazid by Cytochromes P450: Analyzing the molecular mechanism using density functional theory. Chemical Research in Toxicology. 2017;30(11):2060-2073. doi: 10.1021/acs.chemrestox.7b00129
Zhang Y, Heym B, Allen B, et al. The catalase–peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992;358(6387):591–593. doi:10.1038/358591a0
Unissa AN, Subbian S, Hanna LE, et al. Overview on mechanisms of drug resistance in Mycobacterium tuberculosis. Infection, Genetics and Evolution. 2016;45:1–11. doi:10.1016/j.meegid.2016.08.004
Batool Z, Wu Q, Weng G, Shen B. A Review on Isoniazid and Rifampicin-Associated Hepatotoxicity: From Metabolism to Immunity. Archiv der Pharmazie. 2026;359(3):e70204. doi: 10.1002/ardp.70204
Baltz RH. Renaissance in antibacterial discovery from actinomycetes. Current Opinion in Pharmacology. 2008;8(5):557–563. doi:10.1016/j.coph.2008.04.008
Sensi P. History of the development of rifampin. Reviews of Infectious Diseases.1983;5 Suppl 3:S402-406. doi: 10.1093/clinids/5.supplement_3.s402
Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. The Lancet Infectious Diseases. 2014;14(4):327-40. doi: 10.1016/S1473-3099(13)70328-1
Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. International Journal of Tuberculosis and Lung Disease. 2000 Sep;4(9):796-806. Erratum in: International Journal of Tuberculosis and Lung Disease. 2003;7(3):304.
Jindani A, Doré CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. American Journal of Respiratory and Critical Care Medicine. 2003;167(10):1348-54. doi: 10.1164/rccm.200210-1125OC.
Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrobial Agents and Chemotherapy. 2003;47(3):833-6. doi: 10.1128/AAC.47.3.833-836.2003.
Prideaux, B., Via, L., Zimmerman, M. et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nature Medicine. 2015;21:1223-1227. doi: 10.1038/nm.3937
Rosenthal IM, Tasneen R, Peloquin CA, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrobial Agents and Chemotherapy. 2012;56(8):4331-40. doi: 10.1128/AAC.00912-12.
Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Morbidity and Mortality Weekly Report: Recommendations and Reports. 1993;42(RR-9):14-20.
Schmaltz CAS, Demitto FO, Sant'Anna FM, et al. Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different? Memórias do Instituto Oswaldo Cruz. 2019; 11;114:e180420. doi: 10.1590/0074-02760180420.
Stennis NL, Burzynski JN, Herbert C, et al.. Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics. Clinical Infectious Diseases. 2016;62(1):53-59. doi: 10.1093/cid/civ766.
Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell. 2001;104(6):901-12. doi: 10.1016/s0092-8674(01)00286-0.
Jin Y, Gill SK, Kirchhoff PD, Wan B, et al. Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin. Bioorganic & Medicinal Chemistry Letters. 2011;21(20):6094-9. doi: 10.1016/j.bmcl.2011.08.054.
Tanner L, Mashabela GT, Omollo CC, et al. Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy. Microbiology Spectrum. 2021;9(2):e0043421. doi: 10.1128/Spectrum.00434-21.
Lin W, Mandal S, Degen D, et al. Structural Basis of Mycobacterium tuberculosis Transcription and Transcription Inhibition. Molecular Cell. 2017;66(2):169-179.e8. doi: 10.1016/j.molcel.2017.03.001.
Tupin A, Gualtieri M, Roquet-Banères F, et al. Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns. International Journal of Antimicrobial Agents. 2010;35(6):519-23. doi: 10.1016/j.ijantimicag.2009.12.017
Goldstein BP. Resistance to rifampicin: a review. The Journal of Antibiotics. 2014;67(9):625–630. doi:10.1038/ja.2014.107
Mosaei H, Zenkin N. Inhibition of RNA polymerase by rifampicin and rifamycin-like molecules. EcoSal Plus. 2020;9(1):10.1128/ecosalplus.ESP-0017-2019. doi: 10.1128/ecosalplus.ESP-0017-2019.
Kolodkin-Gal I, Hazan R, Gaathon A, et al. Rifampicin-induced mazEF-mediated cell death. Science. 2007;318(5850):652–655. doi: 10.1126/science.1147248
Ramage HR, Connolly LE, Cox JS. Comprehensive functional analysis of Mycobacterium tuberculosis toxin-antitoxin systems: implications for pathogenesis, stress responses, and evolution. PLoS Genetics. 2009;5(12):e1000767. doi: 10.1371/journal.pgen.1000767
Sala A, Bordes P, Genevaux P. Multiple toxin-antitoxin systems in Mycobacterium tuberculosis. Toxins. 2014;6(3):1002-20. doi: 10.3390/toxins6031002
Shi D, Zhou Q, Xu S, et al. Pyrazinamide resistance and pncA mutation profiles in multidrug resistant Mycobacterium tuberculosis. Infection and Drug Resistance. 2022;15:4985–4994. doi: 10.2147/IDR.S368444
Murray JF, Schraufnagel DE, Hopewell PC. Treatment of tuberculosis: a historical perspective. Annals of the American Thoracic Society. 2015;12(12):1749–1759. doi: 10.1513/AnnalsATS.201509-632PS
Chirehwa MT, McIlleron H, Rustomjee R,et al. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy. 2017 Jul 25;61(8):e00490-17. doi: 10.1128/AAC.00490-17.
Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. International Journal of Tuberculosis and Lung Disease. 2003;7(1):6-21
Dickinson JM, Aber VR, Mitchison DA. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium tuberculosis. American Review of Respiratory Disease. 1977;116(4):627-35. doi: 10.1164/arrd.1977.116.4.627
Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of Pyrazinamide Action and Resistance. Microbiology Spectrum. 2014;2(4):MGM2-0023-2013. doi: 10.1128/microbiolspec.MGM2-0023-2013
Wade MM, Zhang Y. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. Journal of Antimicrobial Chemotherapy. 2006;58(5):936-41. doi: 10.1093/jac/dkl358
Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. Journal of Antimicrobial Chemotherapy. 2003;52(5):790-5. doi: 10.1093/jac/dkg446
Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996;64(6):2062-9. doi: 10.1128/iai.64.6.2062-2069.1996
Zimhony O, Vilchèze C, Arai M, Welch JT, Jacobs WR Jr. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. Antimicrobial Agents and Chemotherapy. 2007;51(2):752-4. doi: 10.1128/AAC.01369-06
Corrêa MF, Fernandes JP. Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis. Current Protein & Peptide Science. 2016;17(3):213-9. doi: 10.2174/1389203716666151002114839.
Requena D, Supo-Escalante RR, Sheen P, Zimic M. Studying the dynamics of the drug processing of pyrazinamide in Mycobacterium tuberculosis. PLOS ONE. 2024;19(8):e0309352. doi: 10.1371/journal.pone.0309352.
Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science. 2011;333(6049):1630–1632. doi: 10.1126/science.1208813
Gopal P, Grüber G, Dartois V, Dick T. Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide. Trends in Pharmacological Sciences,Volume 40, Issue 12, 2019, pp 930-940, ISSN 0165-6147. doi:10.1016/j.tips.2019.10.005
Zhang N, Savic RM, Boeree MJ, et al. Optimising pyrazinamide for the treatment of tuberculosis. European Respiratory Journal. 2021; 58: 2002013 DOI: 10.1183/13993003.02013-2020
Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. International Journal of Tuberculosis and Lung Disease. 2012 Jun;16(6):724-32. doi: 10.5588/ijtld.12.0083.
Muliaditan M, Della Pasqua O. Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis. British Journal of Clinical Pharmacology. 2021;87(1):140-151. doi: 10.1111/bcp.14371.
Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial resistance in tuberculosis. Tubercle and Lung Disease. 1998;79(1):3–29. doi: 10.1054/tuld.1998.0002
Sreevatsan S, Pan X, Zhang Y, et al. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrobial Agents and Chemotherapy. 1997;41(3):636-40. doi: 10.1128/AAC.41.3.636.
Juma SP, Maro A, Pholwat S, et al. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania. BMC Infectious Diseases.2019;19(1):129. doi: 10.1186/s12879-019-3757-1.
Shi W, Chen J, Feng J, et al. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. Emerging Microbes & Infections. 2014;3(8):e58. doi: 10.1038/emi.2014.61.
Yee M, Gopal P, Dick T. ClpC1 mutations and resistance. Antimicrobial Agents and Chemotherapy. 2017;61(2):e02342-16. doi: 10.1128/AAC.02342-16
Sun, Q., Li, X., Perez, L.M. et al. The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. Nature Communications. 2020;11,339. doi: 10.1038/s41467-019-14238-3
Hameed HA, Tan Y, Islam MM, et al. Novel mutations in MDR-TB isolates. Infection and Drug Resistance. 2020;13:217–227. doi: 10.2147/IDR.S232546
Whitfield MG, Soeters HM, Warren RM, et al. A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. PLOS ONE. 2015;10(7):e0133869. doi: 10.1371/journal.pone.0133869
Thomas J, Baughn C, Wilkinson R, Shepherd R. A new synthetic compound with antituberculous activity in mice: Ethambutol. American Review of Respiratory Disease. 1961;83:891-893.
Griffith DE, Aksamit T, Brown-Elliott BA, et al. Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. American Journal of Respiratory and Critical Care Medicine.2007;175:367-416. doi: 10.1164/rccm.200604-571ST
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease. Clinical Infectious Diseases. 2020;71:905–913. doi: 10.1093/cid/ciaa1125
Heifets LB. Antimycobacterial drugs. Seminars in Respiratory Infections 1994;9(2):84-103. Erratum in: Semin Respir Infect 1995;10(2):121.
Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985;66:219–225. doi: 10.1016/0041-3879(85)90040-6
Nahid P, Dorman SE, Alipanah N, et al. Treatment of drug-susceptible tuberculosis. Clinical Infectious Diseases. 2016;63:e147–e195. doi: 10.1093/cid/ciw376
Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis. Clinical Infectious Diseases. 2002;34:658–660. doi: 10.1086/338822
Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. International Journal of Tuberculosis and Lung Disease. 2009;13:1320–1330.
Takayama K, Kilburn JO. Inhibition of arabinogalactan synthesis. Antimicrobial Agents and Chemotherapy. 1989;33:1493–1499. doi: 10.1128/AAC.33.9.1493
Jankute M, Grover S, Rana AK, Besra GS. Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets. Future Microbiology. 2012;7(1):129-47. doi: 10.2217/fmb.11.123.
Lee N, Patel P, Nguyen H. Ethambutol. (Updated 2024 May 2). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559050/
Alderwick LJ, Harrison J, Lloyd GS, Birch HL. The Mycobacterial Cell Wall--Peptidoglycan and Arabinogalactan. Cold Spring Harbor Perspectives in Medicine.2015;5(8):a021113. doi: 10.1101/cshperspect.a021113.
Marrakchi H, Lanéelle MA, Daffé M. Mycolic acids: structures and biosynthesis. Chemistry & Biology. 2014;21:67–85. doi: 10.1016/j.chembiol.2013.11.011
Abrahams KA, Besra GS. Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target. Parasitology. 2018;145(2):116-133. doi: 10.1017/S0031182016002377.
Zhao LL, Sun Q, Liu HC, et al. Analysis of embCAB mutations associated with ethambutol resistance in multidrug-resistant mycobacterium tuberculosis isolates from China. Antimicrobial Agents and Chemotherapy. 2015;59(4):2045-50. doi: 10.1128/AAC.04933-14.
Goude R, Amin AG, Chatterjee D, Parish T. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2009;53(10):4138-46. doi: 10.1128/AAC.00162-09
Belanger AE, Besra GS, Ford ME, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(21):11919-24. doi: 10.1073/pnas.93.21.11919.
Telenti A, Philipp WJ, Sreevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Medicine. 1997;3(5):567-70. doi: 10.1038/nm0597-567.
Xu Y, Jia H, Huang H, et al. Mutations found in embCAB, embR, and ubiA genes of ethambutol-sensitive and -resistant Mycobacterium tuberculosis clinical isolates from China. BioMed Research International.2015;2015:951706. doi: 10.1155/2015/951706.
Lingaraju S, Rigouts L, Gupta A, et al. Geographic differences in the contribution of ubiA mutations to high-Level ethambutol resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2016;60(7):4101-5. doi: 10.1128/AAC.03002-15
Safi H, Lingaraju S, Amin A, et al. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes. Nature Genetics.2013;45(10):1190-7. doi: 10.1038/ng.2743
Sharma K, Gupta M, Pathak M, et al. Transcriptional control of the mycobacterial embCAB operon by PknH through a regulatory protein, EmbR, in vivo. Journal of Bacteriology.2006;188(8):2936-44. doi: 10.1128/JB.188.8.2936-2944.2006
Hung TM, Jayanti RP, Lee HY, et al. Recommendation of pharmacokinetics/pharmacodynamics target of ethambutol to suppress tuberculosis resistance: A population pharmacokinetics study on a large prospective cohort. International Journal of Antimicrobial Agents.2023;62(2):106840. doi: 10.1016/j.ijantimicag.2023.106840
Labuda SM, Seaworth B, Dasgupta S, et al. Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis. The Lancet Respiratory Medicine.2024;12(2):e5-e6. doi: 10.1016/S2213-2600(23)00426-5
Johnson & Johnson Receives Approval from U.S. FDA and European Commission for SIRTURO® (bedaquiline). Johnson & Johnson. July 2, 2024. Accessed July 8, 2024. https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-approval-from-u-s-fda-and-european-commission-for-sirturo-bedaquiline
Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. European Respiratory Journal. 2021;57:2003300. doi:10.1183/13993003.03300-2020
Centers for Disease Control and Prevention. Provisional CDC guidance for the use of pretomanid as part of a regimen (BPaL), 2024.
Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. Morbidity and Mortality Weekly Report: Recommendations and Reports. 2013;62(RR-09):1-12. Erratum in: Morbidity and Mortality Weekly Report: Recommendations and Reports. 2013;62(45):906.
Lakshmanan M, Xavier AS. Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis. Journal of Young Pharmacists.2013;5(4):112-5. doi: 10.1016/j.jyp.2013.12.002
Vocat A, Hartkoorn RC, Lechartier B, et al. Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2015;59:4012–4019. doi:10.1128/AAC.00520-15
Singh B, Singh C. Bedaquiline in Drug-Resistant Tuberculosis: A Mini-Review. Current Molecular Pharmacology. 2023;16(3):243-253. doi: 10.2174/1874467215666220421130707. Update in: Current Molecular Pharmacology. 2024;17:e110924233920. doi: 10.2174/187446721701240911110426.
Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223–227. doi:10.1126/science.1106753
Koul A, Dendouga N, Vranckx L, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chemical Biology.2007;3:323–324. doi:10.1038/nchembio884
Haagsma AC, Podasca I, Koul A, et al. Probing the interaction of TMC207 with mycobacterial ATP synthase. PLOS ONE. 2011;6:e23575. doi:10.1371/journal.pone.0023575
Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. Journal of Biological Chemistry. 2008 Sep 12;283(37):25273-25280. doi: 10.1074/jbc.M803899200
Koul A, Vranckx L, Dhar N, et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nature Communications. 2014;5:3369. doi: 10.1038/ncomms4369
Sarathy JP, Gruber G, Dick T. Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline. Antibiotics. 2019;8(4):261. doi: 10.3390/antibiotics8040261
Perrineau S, Lachâtre M, Lê MP, et al. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease. 2019;23(1):99-104. doi: 10.5588/ijtld.18.0042
Zhu H, Xie L, Liu ZQ, et al. Population pharmacokinetics of bedaquiline in patients with drug-resistant TB. International Journal of Tuberculosis and Lung Disease. 2021;25(12):1006-1012. doi: 10.5588/ijtld.21.0158
Healan AM, Griffiss JM, Proskin HM, et al. Impact of rifabutin or rifampin on bedaquiline safety, tolerability, and pharmacokinetics assessed in a randomized clinical trial with healthy adult volunteers. Antimicrobial Agents and Chemotherapy. 2017;62(1):e00855-17. doi: 10.1128/AAC.00855-17
Ismail N, Omar SV, Ismail NA, Peters RPH. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. Data in Brief.2018;20:1975-1983. doi: 10.1016/j.dib.2018.09.057
Chakraborty G, Nath I V A, Sharma M, et al. In silico structural and mechanical insights into bedaquiline resistance associated with high-grade non-synonymous mutations in atpE, mmpR5, and pepQ. Journal of Biomolecular Structure and Dynamics. 2024;42(20):10937-10949. doi: 10.1080/07391102.2023.2259486
Sonnenkalb L, Carter JJ, Spitaleri A, et al. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. The Lancet Microbe. 2023;4(5):e358-e368. doi: 10.1016/S2666-5247(23)00002-2
Omar SV, Ismail F, Ndjeka N, et al. Bedaquiline-resistant tuberculosis associated with Rv0678 mutations. New England Journal of Medicine. 2022;386:93–94. doi: 10.1056/NEJMc2103049.
Guo Q, Bi J, Lin Q, Ye T, et al. Whole genome sequencing identifies novel mutations associated with bedaquiline resistance in Mycobacterium tuberculosis. Frontiers in Cellular and Infection Microbiology.2022;12:807095. doi: 10.3389/fcimb.2022.807095
Chesov E, Chesov D, Maurer FP, et al. Emergence of bedaquiline resistance in a high tuberculosis burden country. European Respiratory Journal. 2022;59(3):2100621. doi: 10.1183/13993003.00621-2021
Snobre J, Villellas MC, Coeck N, et al. Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678. Scientific Reports. 2023;13(1):10444. doi: 10.1038/s41598-023-36955-y
Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2014;58(5):2979-81. doi: 10.1128/AAC.00037-14
Köser CU, Javid B, Liddell K, et al. Drug-resistance mechanisms and tuberculosis drugs. Lancet. 2015;385(9965):305-7. doi: 10.1016/S0140-6736(14)62450-8
Fountain, A. Characterisation of bedaquiline resistance mediated by the M. tuberculosis MmpS5L5 efflux pump. PhD Thesis, 2024. (Apollo - University of Cambridge Repository). doi: 10.17863/CAM.114347
Mallick JS, Nair P, Abbew ET, Van Deun A, et al. Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. JAC-Antimicrobial Resistance.2022;4(2):dlac029. doi: 10.1093/jacamr/dlac029.
Pule CM, Sampson SL, Warren RM, Black PA, van Helden PD, Victor TC, Louw GE. Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. Journal of Antimicrobial Chemotherapy. 2016;71(1):17-26. doi: 10.1093/jac/dkv316
Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. New England Journal of Medicine. 2020;382(10):893–902. doi:10.1056/NEJMoa1901814
Tweed CD, Dawson R, Burger DA, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. The Lancet Respiratory Medicine.2019 Dec;7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2
Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis. PLOS Medicine.2006;3(11):e466. doi:10.1371/journal.pmed.0030466
Patel MN, Patel AJ, Nandpal MN, et al. Advancing against drug-resistant tuberculosis. Naunyn-Schmiedeberg’s Archives of Pharmacology.2025. doi:10.1007/s00210-024-03466-0
Blair HA, Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs. 2015;75(1):91-100. doi: 10.1007/s40265-014-0331-4.
Stinson K, Kurepina N, Venter A, et al. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration. Antimicrobial Agents and Chemotherapy. 2016;60(6):3316-22. doi: 10.1128/AAC.03014-15
Wen S, Jing W, Zhang T, et al. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. European Journal of Clinical Microbiology & Infectious Diseases. 2019 Jul;38(7):1293-1296. doi: 10.1007/s10096-019-03551-w
Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008;322(5906):1392–1395. doi:10.1126/science.1164571
Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X
Baptista R, Fazakerley DM, Beckmann M, et al. Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824). Scientific Reports.2018;8(1):5084. doi: 10.1038/s41598-018-23110-1
Nguyen TVA, Nguyen QH, Nguyen TNT, et al. Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice. International Journal of Antimicrobial Agents.2023;62(4):106953. doi: 10.1016/j.ijantimicag.2023.106953
Hayashi M, Nishiyama A, Kitamoto R, et al. Adduct Formation of Delamanid with NAD in Mycobacteria. Antimicrobial Agents and Chemotherapy. 2020;64(5):e01755-19. doi: 10.1128/AAC.01755-19
Fujiwara M, Kawasaki M, Hariguchi N, et al. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland). 2018;108:186-194. doi: 10.1016/j.tube.2017.12.006. Erratum in: Tuberculosis (Edinburgh, Scotland). 2018;110:122. doi: 10.1016/j.tube.2018.03.004
Khoshnood S, Taki E, Sadeghifard N, et al. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis. Frontiers in Microbiology. 2021;12:717045. doi: 10.3389/fmicb.2021.717045
Lee BM, Harold LK, Almeida DV, et al. Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering. PLOS Pathogens.2020;16(2):e1008287. doi: 10.1371/journal.ppat.1008287
Rupasinghe P, Reenaers R, Vereecken J, et al. Refined understanding of the impact of the Mycobacterium tuberculosis complex diversity on the intrinsic susceptibility to pretomanid. Microbiology Spectrum. 2024;12(3):e0007024. doi: 10.1128/spectrum.00070-24
Mudde SE, Upton AM, Lenaerts A, et al. Delamanid or pretomanid? Journal of Antimicrobial Chemotherapy. 2022;77(4):880–902. doi:10.1093/jac/dkab505
Sharma A, Chatterjee P, Shastry S. Delamanid or pretomanid for treatment of multidrug resistant tuberculosis---spoilt for choice? Indian Journal of Tuberculosis.2026;73(2):284-285. doi: 10.1016/j.ijtb.2025.09.005
Rifat D, Li SY, Ioerger T, et al. Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2021;65(1):e01948-20. doi:10.1128/AAC.01948-20
Haver HL, Chua A, Ghode P, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2015;59(9):5316-23. doi: 10.1128/AAC.00308-15
Gupta R, Wells CD, Hittel N, Hafkin J, Geiter LJ. Delamanid in the treatment of multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease. 2016;20(12):33-37. doi: 10.5588/ijtld.16.0125
Mok S, Roycroft E, Flanagan PR, et al. Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates. Journal of Antimicrobial Chemotherapy. 2023;78(11):2637-2644. doi: 10.1093/jac/dkad252
Singh B, Cocker D, Ryan H, et al. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database of Systematic Reviews.2019;3:CD012836. doi:10.1002/14651858.CD012836.pub2
Rendon A, Tiberi S, Scardigli A, et al. Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. Journal of Thoracic Disease. 2016;8(10):2666-2671. doi: 10.21037/jtd.2016.10.14
Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrobial Agents and Chemotherapy. 2009;53(12):5265-74. doi: 10.1128/AAC.00871-09
Jadhavar PS, Vaja MD, Dhameliya TM, et al. Oxazolidinones as Anti-tubercular Agents: Discovery, Development and Future Perspectives. Current Medicinal Chemistry. 2015;22(38):4379-97. doi: 10.2174/0929867323666151106125759
Bolhuis MS, Akkerman OW, Sturkenboom MGG, et al. Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment. Clinical Infectious Diseases. 2018;67(suppl_3):S327-S335. doi: 10.1093/cid/ciy625
Bigelow KM, Tasneen R, Chang YS, et al. Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model. Antimicrobial Agents and Chemotherapy. 2020;64(10):e01178-20. doi: 10.1128/AAC.01178-20
Diekema DI, Jones RN. Oxazolidinones: a review. Drugs. 2000;59(1):7-16. doi: 10.2165/00003495-200059010-00002
Lin DF, Zhang YY, Wu JF, et al. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. International Journal of Antimicrobial Agents.2008;32(3):241-9. doi: 10.1016/j.ijantimicag.2008.04.004
Gopalaswamy R, Subbian S. The power of resistance: mechanisms of antimicrobial resistance in Mycobacterium tuberculosis and its impact on tuberculosis management. Clinical Microbiology Reviews. 2026;39(1):e0019425. doi: 10.1128/cmr.00194-25. Erratum in: Clinical Microbiology Reviews. 2026:e0009326. doi: 10.1128/cmr.00093-26
Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Current Drug Targets – Infectious Disorders.2001;1(2):181-99. doi: 10.2174/1568005014606099
Antal EJ, Hendershot PE, Batts DH, et al. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. Journal of Clinical Pharmacology.2001;41(5):552-62. doi: 10.1177/00912700122010294
Du J, Gao J, Yu Y, et al. Low rate of acquired linezolid resistance in multidrug-resistant tuberculosis treated with bedaquiline-linezolid combination. Frontiers in Microbiology. 2021;12:655653. doi: 10.3389/fmicb.2021.655653
Rui Pi, Qingyun Liu, Qi Jiang, et al. Characterization of linezolid-resistance-associated mutations in Mycobacterium tuberculosis through WGS, Journal of Antimicrobial Chemotherapy. 2019;74(7):1795–1798. doi: 10.1093/jac/dkz150
Zhou W, Wang Q, Nie W, et al. Acquired linezolid resistance in DR-TB: genotype-phenotype discordance and molecular heterogeneity in a retrospective cohort. BMC Infectious Diseases. 2016;26, 541. doi: 10.1186/s12879-026-12869-8
Gan WC, Ng HF, Ngeow YF. Mechanisms of linezolid resistance in Mycobacteria. Pharmaceuticals 2023;16(6), 784. doi: 10.3390/ph16060784
Peloquin CA. Quinolones and tuberculosis. The Annals of Pharmacotherapy.1996;30(9):1034-5. doi: 10.1177/106002809603000922
Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. The Lancet Infectious Diseases. 2003;3:432–442. doi:10.1016/S1473-3099(03)00671-6
Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. European Respiratory Journal. 2017;49(3):1602308. doi: 10.1183/13993003.02308-2016
Koh WJ, Lee SH, Kang YA, et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2013;188(7):858-64. doi: 10.1164/rccm.201303-0604OC
Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2003;47(2):653-7. doi: 10.1128/AAC.47.2.653-657.2003
Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2003;168(11):1342-5. doi: 10.1164/rccm.200305-682OC
Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrobial Agents and Chemotherapy. 2004;48(3):780-2. doi: 10.1128/AAC.48.3.780-782.2004
Takiff HE, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrobial Agents and Chemotherapy. 1994;38(4):773-80. doi: 10.1128/AAC.38.4.773.
Collin F, Karkare S, Maxwell A. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Applied Microbiology and Biotechnology. 2011;92(3):479-97. doi: 10.1007/s00253-011-3557-z
Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews. 1997;61(3):377-92. doi: 10.1128/mmbr.61.3.377-392.1997.
Devasia RA, Blackman A, May C, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. Journal of Antimicrobial Chemotherapy. 2009;63(6):1173-8. doi: 10.1093/jac/dkp096
Maruri F, Sterling TR, Kaiga AW, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. Journal of Antimicrobial Chemotherapy. 2012;67(4):819-31. doi: 10.1093/jac/dkr566.
Redgrave LS, Sutton SB, Webber MA, et al. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends in Microbiology. 2014;22(8):438-45. doi: 10.1016/j.tim.2014.04.007.
Carr W, Kurbatova E, Starks A, et al. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. Morbidity and Mortality Weekly Report. 2022;71(8):285-289. doi: 10.15585/mmwr.mm7108a1
Barry VC, Belton JG, Conalty ML, et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature. 1957;179(4568):1013-5. doi: 10.1038/1791013a0
Holdiness MR. Clinical pharmacokinetics of clofazimine. A review. Clinical Pharmacokinetics.1989;16(2):74-85. doi: 10.2165/00003088-198916020-00002
Reddy VM, O'Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. Journal of Antimicrobial Chemotherapy. 1999;43(5):615-23. doi: 10.1093/jac/43.5.615
Abdelwahab MT, Court R, Everitt D, et al. Effect of clofazimine concentration on QT prolongation in patients treated for tuberculosis. Antimicrobial Agents and Chemotherapy. 2021;65(7):e0268720. doi: 10.1128/AAC.02687-20
Allouchery M, Logerot S, Cottin J, et al. Antituberculosis drug-associated DRESS: A Case Series. The Journal of Allergy and Clinical Immunology: In Practice.2018;6(4):1373-1380. doi: 10.1016/j.jaip.2017.11.021
Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. Journal of the American Academy of Dermatology. 1995;32(2 Pt 1):241-7. doi: 10.1016/0190-9622(95)90134-5
Khatun S, Afrin S, Alam S. Molecular mechanism of clofazimine resistance in tuberculosis. Journal of Infectious Diseases and Immunity. 2023; 15(2): 41-52. doi: 10.5897/JIDI2020.0199
Lechartier B, Cole ST. Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2015;59(8):4457-63. doi: 10.1128/AAC.00395-15
Bhanu MLS. Anti-tuberculosis drugs and mechanisms of action. International Journal of Infectious Diseases. 2023;4(2):1-7.
Stadler JAM, Maartens G, Meintjes G, et al. Clofazimine for the treatment of tuberculosis. Frontiers in Pharmacology. 2023;14:1100488. doi: 10.3389/fphar.2023.1100488
Iroh Tam P, Arnold SLM, Barrett LK, et al. Clofazimine for Treatment of Cryptosporidiosis in Human Immunodeficiency Virus Infected Adults: An Experimental Medicine, Randomized, Double-blind, Placebo-controlled Phase 2a Trial. Clinical Infectious Diseases. 2021;73(2):183-191. doi: 10.1093/cid/ciaa421
Somoskovi A, Bruderer V, Hömke R, et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. European Respiratory Journal. 2015;45(2):554-7. doi: 10.1183/09031936.00142914
Zhang L, Zhang Y, Li Y, et al. Rv1453 is associated with clofazimine resistance in Mycobacterium tuberculosis. Microbiology Spectrum. 2023;11(5):e0000223. doi: 10.1128/spectrum.00002-23
Park S, Jung J, Kim J, Han SB, et al. Investigation of clofazimine resistance and genetic mutations in drug-resistant Mycobacterium tuberculosis isolates. Journal of Clinical Medicine. 2022;11(7):1927. doi: 10.3390/jcm11071927
Peloquin CA, Davies GR. The treatment of tuberculosis. Clin Pharmacology & Therapeutics. 2021;110(6):1455-1466. doi: 10.1002/cpt.2261
Bruning JB, Murillo AC, Chacon O, et al. Structure of the Mycobacterium tuberculosis D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine. Antimicrobial Agents and Chemotherapy. 2011;55(1):291-301. doi: 10.1128/AAC.00558-10
Batson S, de Chiara C, Majce V, et al. Inhibition of D-Ala:D-Ala ligase through a phosphorylated form of the antibiotic D-cycloserine. Nature Communications. 2017;8(1):1939. doi: 10.1038/s41467-017-02118-7
Mulubwa M, Mugabo P. Amount of Cycloserine Emanating from terizidone metabolism and relationship with hepatic function in patients with drug-resistant tuberculosis. Drugs in R&D. 2019;19(3):289-296. doi: 10.1007/s40268-019-00281-4
Alghamdi WA, Alsultan A, Al-Shaer MH, et al. Cycloserine population pharmacokinetics and pharmacodynamics in patients with tuberculosis. Antimicrobial Agents and Chemotherapy. 2019;63(5):e00055-19. doi: 10.1128/AAC.00055-19
Chen J, Zhang S, Cui P, et al. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy. 2017;72(12):3272-3276. doi: 10.1093/jac/dkx316
Chauhan A, Kumar M, Kumar A, Kanchan K. Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs. Life Sciences. 2021;274:119301. doi: 10.1016/j.lfs.2021.119301
Evangelopoulos D, Prosser GA, Rodgers A, et al. Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes. Nature Communications. 2019;10:4177. doi:10.1038/s41467-019-12074-z
Desjardins CA, Cohen KA, Munsamy V, et al. Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nature Genetics. 2016;48(5):544–551. doi:10.1038/ng.3545
Jeong, JA., Oh, JI. Alanine dehydrogenases in mycobacteria. Journal of Microbiology.2019;57: 81–92. doi:10.1007/s12275-019-8543-7
Nakatani Y, Opel-Reading HK, Merker M, et al. Role of alanine racemase mutations in Mycobacterium tuberculosis d-cycloserine resistance. Antimicrobial Agents and Chemotherapy. 2017;61(12):e01575-17. doi: 10.1128/AAC.01575-17
Auclair B, Nix DE, Adam RD, et al. Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrobial Agents and Chemotherapy. 2001;45(3):810–814. doi:10.1128/AAC.45.3.810-814.2001
Mugabo P, Mulubwa M. Ethionamide population pharmacokinetics/pharmacodynamics and therapeutic implications in South African adult patients with drug-resistant tuberculosis. British Journal of Clinical Pharmacology. 2021;87(10):3863-3870. doi: 10.1111/bcp.14795
Baulard AR, Betts JC, Engohang-Ndong J, et al. Activation of the pro-drug ethionamide is regulated in mycobacteria. Journal of Biological Chemistry. 2000;275(36):28326-31. doi: 10.1074/jbc.M003744200
Vale N, Gomes P, Santos HA. Metabolism of the antituberculosis drug ethionamide. Current Drug Metabolism.2013;14(1):151-8.
Brammachary U, Ramachandra V, Palavesam S, et al. Mechanisms and Action of Drug Resistance on Mycobacterium tuberculosis (Internet). New Insights in Antibiotic Resistance and Pneumococcal Vaccines. IntechOpen; 2025. doi: 10.5772/intechopen.108943
Ushtanit A, Kulagina E, Mikhailova Y, et al. Molecular determinants of ethionamide resistance in clinical isolates of Mycobacterium tuberculosis. Antibiotics. 2022;11(2):133. doi: 10.3390/antibiotics11020133
Islam MM, Tan Y, Hameed HMA, et al. Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. Clinical Microbiology and Infection. 2019;25(8):1041.e1-1041.e7. doi: 10.1016/j.cmi.2018.12.008
Hicks ND, Carey AF, Yang J, et al. Bacterial genome-wide association identifies novel factors that contribute to ethionamide and prothionamide susceptibility in Mycobacterium tuberculosis. mBio. 2019;10(2):e00616-19. doi: 10.1128/mBio.00616-19
Tan Y, Su B, Zheng H, et al. Molecular Characterization of prothionamide-resistant Mycobacterium tuberculosis isolates in Southern China. Frontiers in Microbiology. 2017;8:2358. doi: 10.3389/fmicb.2017.02358
Morlock GP, Metchock B, Sikes D, et al. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrobial Agents and Chemotherapy. 2003;47(12):3799-805. doi: 10.1128/AAC.47.12.3799-3805.2003
Cao B, Mijiti X, Deng LL, et al. Genetic characterization conferred co-resistance to isoniazid and ethionamide in Mycobacterium tuberculosis isolates from Southern Xinjiang, China. Infection and Drug Resistance. 2023;16:3117-3135. doi: 10.2147/IDR.S407525
Sakallioglu IT, Maroli AS, De Lima Leite A, et al. Multi-omics investigation into the mechanism of action of an anti-tubercular fatty Acid analogue. Journal of the American Chemical Society. 2022;144(46):21157-21173. doi: 10.1021/jacs.2c08238
de Welzen L, Eldholm V, Maharaj K, et al. Whole-Transcriptome and -genome analysis of extensively drug-resistant Mycobacterium tuberculosis clinical isolates identifies downregulation of ethA as a mechanism of ethionamide resistance. Antimicrobial Agents and Chemotherapy. 2017;61(12):e01461-17. doi: 10.1128/AAC.01461-17
Abulfathi AA, Donald PR, Adams K, et al. The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance. British Journal of Clinical Pharmacology. 2020;86:2123-2132. doi: 10.1111/bcp.14395
Zhang T, Jiang G, Wen S, et al. Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis. Infection and Drug Resistance. 2019;12:825-829. doi: 10.2147/IDR.S200697
Chakraborty S, Gruber T, Barry CE 3rd, Boshoff HI, Rhee KY. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science. 2013;339(6115):88-91. doi: 10.1126/science.1228980
Zheng J, Rubin EJ, Bifani P, et al. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. Journal of Biological Chemistry. 2013;288(32):23447-56. doi: 10.1074/jbc.M113.475798 Erratum in: Journal of Biological Chemistry. 2013 Oct 4;288(40):28951
Mathys V, Wintjens R, Lefevre P, et al. Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2009;53(5):2100-9. doi: 10.1128/AAC.01197-08
Adilakshmi T, Ayling PD, Ratledge C. Mutational analysis of a role for salicylic acid in iron metabolism of Mycobacterium smegmatis. Journal of Bacteriology. 2000;182(2):264-71. doi: 10.1128/JB.182.2.264-271.2000
Peloquin CA, Henshaw TL, Huitt GA, et al. Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy. 1994 J;14(1):40-6. doi: 10.1002/j.1875-9114.1994.tb02787.x.
Wei W, Yan H, Zhao J, et al. Multi-omics comparisons of p-aminosalicylic acid (PAS) resistance in folC mutated and un-mutated Mycobacterium tuberculosis strains. Emerging Microbes & Infections. 2019;8(1):248-261. doi: 10.1080/22221751.2019.1568179
Pandey B, Grover S, Kaur J, Grover A. Analysis of mutations leading to para-aminosalicylic acid resistance in Mycobacterium tuberculosis. Scientific Reports. 2019;9(1):13617. doi: 10.1038/s41598-019-48940-5
Howe MD, Kordus SL, Cole MS, et al. Methionine antagonizes para-aminosalicylic acid activity via affecting folate precursor biosynthesis in Mycobacterium tuberculosis. Frontiers in Cellular and Infection Microbiology. 2018;8:399. doi: 10.3389/fcimb.2018.00399
Ahmad Z, Makaya NH, Grosset J. History of drug discovery: early evaluation studies and lessons learnt from them. In: Antituberculosis chemotherapy, Donald PR, van Helden PD (eds). Progress in Respiratory Research. 2011; 40, 2-9.
Schaaf HS, Seddon JA, Caminero JA. Second-line Antituberculosis Drugs: Current Knowledge, Recent Research Findings and Controversies. In: Donald PR, Van Helden PD (eds.). Antituberculosis Chemotherapy. Karger Medical and Scientific Publishers. 2011;pp. 81-95. ISBN: 978-3-8055-9627-5
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update.
Davidson PT, Le HQ. Drug treatment of tuberculosis--1992. Drugs. 1992;43(5):651–673. doi:10.2165/00003495-199243050-00003
Okwera A, Johnson JL, Vjecha MJ, et al. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults. International Journal of Tuberculosis and Lung Disease. 1997;1(5):441-445.
Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet. 1991;337(8742):627-630. doi:10.1016/0140-6736(91)92447-a
Rieder HL, Arnadottir T, Trébucq A, Enarson DA. Tuberculosis treatment: dangerous regimens?. International Journal of Tuberculosis and Lung Disease. 2001;5(1):1-3.
Dover LG, Alahari A, Gratraud P, et al. EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrobial Agents and Chemotherapy. 2007;51(3):1055-1063. doi:10.1128/AAC.01063-06
Grzegorzewicz AE, Korduláková J, Jones V, et al. A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. Journal of Biological Chemistry. 2012;287(46):38434-41. doi: 10.1074/jbc.M112.400994
Coxon GD, Craig D, Corrales RM, et al. Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues. PLoS ONE 2013; 8(1): e53162. doi: 10.1371/journal.pone.0053162
Belardinelli, J.M. and Morbidoni, H.R. Resistance to thiacetazone in Mycobacterium tuberculosis and Mycobacterium kansasii. Molecular Microbiology 2012; 86: 568-579. doi: 10.1111/mmi.12005
Glickman MS, Cox JS, Jacobs WR Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence and virulence of Mycobacterium tuberculosis. Molecular Cell. 2000;5(4):717–727. doi:10.1016/S1097-2765(00)80250-6
Alahari A, Trivelli X, Guérardel Y, et al. Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in Mycobacteria. PLoS ONE 2007; 2(12): e1343. doi: 10.1371/journal.pone.0001343
Jowsey WJ, Cook GM, McNeil MB. Antibiotic resistance in Mycobacterium tuberculosis alters tolerance to cell wall-targeting inhibitors. JAC-Antimicrobial Resistance. 2024;6(3):dlae086. doi: 10.1093/jacamr/dlae086
Alahari A, Alibaud L, Trivelli X, et al. Mycolic acid methyltransferase, MmaA4, is necessary for thiacetazone susceptibility in Mycobacterium tuberculosis. Molecular Microbiology.2009;71(5):1263-77. doi: 10.1111/j.1365-2958.2009.06604.x
Cantaloube S, Veyron-Churlet R, Haddache N, et al. The Mycobacterium tuberculosis FAS-II dehydratases and methyltransferases define the specificity of the mycolic acid elongation complexes. PLOS ONE. 2011;6(12):e29564. doi: 10.1371/journal.pone.0029564
Sikandar M, Xing L. Advances in the mechanisms of drug resistance of Mycobacterium tuberculosis. Microbial Pathogenesis.2025:107861. doi: 10.1016/j.micpath.2025.107861
Farjallah A, Chiarelli LR, Forbak M, et al. A coumarin-based analogue of thiacetazone as dual covalent inhibitor and potential fluorescent label of HadA in Mycobacterium tuberculosis. ACS Infectious Diseases. 2021; 7 (3), 552-565. DOI: 10.1021/acsinfecdis.0c00325
World Health Organization. Global tuberculosis report 2024. Geneva: WHO; 2024. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024
Caminero JA, Sotgiu G, Zumla A, et al. Treatment of multidrug-resistant tuberculosis: evidence and controversies. International Journal of Tuberculosis and Lung Disease. 2006;10(8):829–837.
Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. Journal of Infection and Public Health. 2014;7(2):75–91. doi:10.1016/j.jiph.2013.09.001
Ramirez MS, Tolmasky ME. Amikacin: uses, resistance, and prospects for inhibition. Molecules. 2017;22(12):E2267. doi:10.3390/molecules22122267
Ying L, Zhu H, Shoji S, et al. Roles of specific aminoglycoside–ribosome interactions in the inhibition of translation. RNA. 2019;25(2):247-254. doi:10.1261/rna.068460.118
Borovinskaya MA, Pai RD, Zhang W, et al. Structural basis for aminoglycoside inhibition of bacterial ribosome recycling. Nature Structural & Molecular Biology. 2007;14(8):727-732. doi:10.1038/nsmb1271
Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. The BMJ. 1948;2(4588):1009–1015. doi:10.1136/bmj.2.4588.1009
Moazed D, Noller HF. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature. 1987;327(6121):389–394. doi:10.1038/327389a0
Sreevatsan S, Pan X, Stockbauer KE, et al. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrobial Agents and Chemotherapy. 1996;40(4):1024-6. doi: 10.1128/AAC.40.4.1024
Okamoto S, Tamaru A, Nakajima C, et al. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Molecular Microbiology. 2007;63(4):1096-106. doi: 10.1111/j.1365-2958.2006
Wong SY, Lee JS, Kwak HK, et al. Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2011;55(6):2515-22. doi: 10.1128/AAC.01814-10
Rocha DMGC, Magalhães C, Cá B, et al. Heterogeneous streptomycin resistance level among Mycobacterium tuberculosis strains from the same transmission cluster. Frontiers in Microbiology. 2021;12:659545. doi: 10.3389/fmicb.2021.659545
Deventer AT, Stevens CE, Stewart A, et al. Antibiotic tolerance among clinical isolates: mechanisms, detection, prevalence, and significance. Clinical Microbiology Reviews. 2024;37(4):e0010624. doi: 10.1128/cmr.00106-24
Sirgel FA, Tait M, Warren RM, et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microbial Drug Resistance. 2012;18(2):193-7. doi: 10.1089/mdr.2011.0063
Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2005;49(8):3192-7. doi: 10.1128/AAC.49.8.3192-3197.2005
Ye M, Yuan W, Molaeipour L, et al. Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis. Annals of Clinical Microbiology and Antimicrobials. 2021;20(1):73. doi: 10.1186/s12941-021-00478-z
Guo Y, Yang J, Wang H, et al. Key resistance-associated mutations in multidrug-resistant tuberculosis: a genomic study from Shanghai, China, with a focus on aminoglycosides. BMC Microbiology. 2025;25(1):702. doi: 10.1186/s12866-025-04446-x
Sowajassatakul, A., Prammananan, T., Chaiprasert, A. et al. Overexpression of eis without a mutation in promoter region of amikacin- and kanamycin-resistant Mycobacterium tuberculosis clinical strain. Annals of Clinical Microbiology and Antimicrobials. 2018;17, 33. doi: 10.1186/s12941-018-0285-6
Lilic M, Darst SA, Campbell EA. Structural basis of transcriptional activation by the Mycobacterium tuberculosis intrinsic antibiotic-resistance transcription factor WhiB7. Molecular Cell. 2021;81(14):2875-2886.e5. doi: 10.1016/j.molcel.2021.05.017
Balganesh M, Dinesh N, Sharma S, et al. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrobial Agents and Chemotherapy. 2012;56(5):2643-51. doi: 10.1128/AAC.06003-11
Böttger EC. Resistance to drugs targeting protein synthesis in mycobacteria. Trends in Microbiology.1994;2(10):416-21. doi: 10.1016/0966-842x(94)90622-x
Sowajassatakul A, Prammananan T, Chaiprasert A, et al. Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand. BMC Microbiology. 2014;14:165. doi: 10.1186/1471-2180-14-165
Johansen SK, Maus CE, Plikaytis BB, et al. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs. Molecular Cell. 2006;23(2):173-82. doi: 10.1016/j.molcel.2006.05.044. PMID: 16857584
Li W, Zhang G. Detection and various environmental factors of antibiotic resistance gene horizontal transfer. Environmental Research. 2022;212(Pt B):113267. doi: 10.1016/j.envres.2022.113267
Hugonnet JE, Tremblay LW, Boshoff HI, et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science. 2009;323(5918):1215-8. doi: 10.1126/science.1167498
Yan W, Zheng Y, Dou C, et al. The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development. Molecular Biomedicine. 2022;3(1):48. doi: 10.1186/s43556-022-00106-y
Chambers HF, Turner J, Schecter GF, et al. Imipenem for treatment of tuberculosis in mice and humans. Antimicrobial Agents and Chemotherapy. 2005;49(7):2816-21. doi: 10.1128/AAC.49.7.2816-2821.2005
Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry. 2007;46(43):11998-2004. doi: 10.1021/bi701506h
Nadler JP, Berger J, Nord JA, et al. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest. 1991;99(4):1025-6. doi: 10.1378/chest.99.4.1025
Pandey N, Cascella M. Beta-Lactam Antibiotics. (Updated 2023 Jun 4). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545311/
Kumar P, Kaushik A, Lloyd EP, et al. Non-classical transpeptidases yield insight into new antibacterials. Nature Chemical Biology. 2017;13(1):54-61. doi: 10.1038/nchembio.2237
Mainardi JL, Hugonnet JE, Rusconi F, et al. Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem. Journal of Biological Chemistry. 2007;282(42):30414-22. doi: 10.1074/jbc.M704286200
De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. European Respiratory Journal. 2013;41(6):1386-92. doi: 10.1183/09031936.00124312
Tiberi S, Sotgiu G, D'Ambrosio L, et al. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal. 2016;47(6):1758-66. doi: 10.1183/13993003.00214-2016
Holzgrabe U. Meropenem-clavulanate: a new strategy for the treatment of tuberculosis? ChemMedChem. 2009;4(7):1051-3. doi: 10.1002/cmdc.200900155
Tiberi S, Sotgiu G, D'Ambrosio L, et al. Effectiveness and safety of imipenem-clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. Clinical Infectious Diseases. 2016;62(9):1188-90. doi: 10.1093/cid/ciw088
Norrby SR, Björnegård B, Ferber F, et al. Pharmacokinetics of imipenem in healthy volunteers. Journal of Antimicrobial Chemotherapy. 1983;12 Suppl D:109-24. doi: 10.1093/jac/12.suppl_d.109
Hazra S, Xu H, Blanchard JS. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry. 2014;53(22):3671-8. doi: 10.1021/bi500339j
Pahuja I, Verma A, Ghoshal A, et al. Biapenem, a carbapenem antibiotic, elicits Mycobacteria specific immune responses and reduces the recurrence of tuberculosis. Microbiology Spectrum. 2023;11(4):e0085823. doi: 10.1128/spectrum.00858-23
Makarov V, Lechartier B, Zhang M, et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Molecular Medicine.2014;6(3):372–383. doi:10.1002/emmm.201303575
Maranchick NF, Peloquin CA, Haley CA. Linezolid dosing and pharmacokinetics in North American patients with tuberculosis. Clinical Infectious Diseases. 2025;81(4):830-837. doi: 10.1093/cid/ciaf027
Singh R, Barry CE 3rd, Boshoff HI. The three RelE homologs of Mycobacterium tuberculosis have individual, drug-specific effects on bacterial antibiotic tolerance. Journal of Bacteriology.2010;192(5):1279-91. doi: 10.1128/JB.01285-09 Erratum in: Journal of Bacteriology.2020;202(24):e00554-20. doi: 10.1128/JB.00554-20
Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. The Lancet Infectious Diseases. 2016;16(4):e34–e46. doi:10.1016/S1473-3099(16)00070-0